肝硬化腹水患者限钠治疗已沿用 10 0余年 ,为国内外公认 ,是肝硬化腹水患者重要治疗措施之一。但限钠治疗可导致血浆钠及渗透压下降 ,利尿剂作用减弱 ,腹水消失时间延长 ,诱发低渗性脑病及肝肾综合征 (ＨＲＳ)等严重后果。近 10余年对肝硬化腹水患者进行限钠与不限钠及静脉输注 Patients with cirrhosis ascites limited sodium treatment has been used for more than 10 years, is recognized at home and abroad, is one of the important treatment of patients with cirrhosis and ascites. However, limited sodium treatment can lead to decreased plasma sodium and osmolality, diuretic effect weakened ascites disappear longer, induced hypotonic encephalopathy and hepatorenal syndrome (HRS) and other serious consequences. Nearly 10 years of cirrhosis patients with sodium and limited sodium and intravenous infusion